Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 5 | 2015 | 259 | 1.340 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2017 | 145 | 1.180 |
Why?
|
Bronchoscopy | 9 | 2017 | 47 | 0.990 |
Why?
|
Pneumonia | 2 | 2015 | 68 | 0.620 |
Why?
|
Adrenal Cortex Hormones | 2 | 2017 | 122 | 0.510 |
Why?
|
Hispanic Americans | 7 | 2016 | 940 | 0.480 |
Why?
|
Self Care | 1 | 2015 | 144 | 0.470 |
Why?
|
Bronchial Neoplasms | 1 | 2013 | 5 | 0.430 |
Why?
|
Transients and Migrants | 6 | 2016 | 290 | 0.430 |
Why?
|
Cryotherapy | 1 | 2013 | 13 | 0.430 |
Why?
|
Male | 27 | 2019 | 19143 | 0.430 |
Why?
|
Bronchodilator Agents | 2 | 2017 | 49 | 0.430 |
Why?
|
Scopolamine Derivatives | 1 | 2012 | 5 | 0.410 |
Why?
|
Androstadienes | 1 | 2012 | 17 | 0.410 |
Why?
|
Albuterol | 1 | 2012 | 19 | 0.410 |
Why?
|
Female | 25 | 2019 | 19939 | 0.400 |
Why?
|
Physicians | 1 | 2014 | 158 | 0.400 |
Why?
|
Middle Aged | 18 | 2017 | 11804 | 0.390 |
Why?
|
Intensive Care Units | 2 | 2016 | 110 | 0.380 |
Why?
|
Adult | 18 | 2016 | 9339 | 0.380 |
Why?
|
Lung Neoplasms | 5 | 2017 | 412 | 0.370 |
Why?
|
Monitoring, Physiologic | 1 | 2010 | 72 | 0.360 |
Why?
|
Blood Pressure Determination | 1 | 2010 | 100 | 0.350 |
Why?
|
Humans | 32 | 2019 | 31974 | 0.350 |
Why?
|
Aged | 14 | 2017 | 10294 | 0.330 |
Why?
|
Oxygen | 1 | 2009 | 142 | 0.310 |
Why?
|
Prevalence | 8 | 2015 | 981 | 0.310 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2019 | 58 | 0.310 |
Why?
|
Exercise Test | 1 | 2009 | 227 | 0.310 |
Why?
|
Walking | 1 | 2009 | 209 | 0.310 |
Why?
|
Respiratory Tract Diseases | 3 | 2014 | 34 | 0.310 |
Why?
|
Pulmonary Medicine | 4 | 2015 | 11 | 0.300 |
Why?
|
Young Adult | 10 | 2016 | 2635 | 0.280 |
Why?
|
Aged, 80 and over | 6 | 2016 | 3988 | 0.250 |
Why?
|
Pesticides | 2 | 2016 | 199 | 0.240 |
Why?
|
Endosonography | 2 | 2015 | 56 | 0.240 |
Why?
|
Agriculture | 5 | 2014 | 186 | 0.240 |
Why?
|
Age Factors | 5 | 2014 | 1187 | 0.240 |
Why?
|
Occupational Exposure | 2 | 2016 | 232 | 0.240 |
Why?
|
Postural Balance | 1 | 2016 | 181 | 0.230 |
Why?
|
Adolescent | 8 | 2015 | 3537 | 0.230 |
Why?
|
North Carolina | 10 | 2016 | 1514 | 0.210 |
Why?
|
Occupational Diseases | 2 | 2015 | 81 | 0.210 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 244 | 0.210 |
Why?
|
Smoking | 3 | 2015 | 497 | 0.210 |
Why?
|
Clinical Competence | 2 | 2015 | 333 | 0.200 |
Why?
|
Postoperative Complications | 2 | 2017 | 776 | 0.190 |
Why?
|
Sleep | 2 | 2019 | 92 | 0.180 |
Why?
|
Agricultural Workers' Diseases | 2 | 2011 | 85 | 0.180 |
Why?
|
Ultrasonography, Interventional | 2 | 2012 | 53 | 0.180 |
Why?
|
Conscious Sedation | 2 | 2017 | 24 | 0.170 |
Why?
|
Socioeconomic Factors | 3 | 2016 | 422 | 0.170 |
Why?
|
Reproducibility of Results | 2 | 2014 | 762 | 0.170 |
Why?
|
United States | 4 | 2016 | 3931 | 0.170 |
Why?
|
Foreign Bodies | 2 | 2009 | 30 | 0.160 |
Why?
|
Age Distribution | 3 | 2014 | 206 | 0.160 |
Why?
|
Preoperative Care | 1 | 2019 | 114 | 0.160 |
Why?
|
Patient Care Team | 1 | 2019 | 129 | 0.160 |
Why?
|
Age of Onset | 2 | 2015 | 94 | 0.150 |
Why?
|
Depression | 2 | 2012 | 444 | 0.150 |
Why?
|
Bronchoalveolar Lavage | 2 | 2017 | 13 | 0.150 |
Why?
|
Cross-Sectional Studies | 4 | 2014 | 1532 | 0.150 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2017 | 6 | 0.150 |
Why?
|
Retrospective Studies | 4 | 2014 | 3502 | 0.150 |
Why?
|
Health Care Surveys | 2 | 2016 | 185 | 0.140 |
Why?
|
Cough | 1 | 2017 | 19 | 0.140 |
Why?
|
Airway Obstruction | 2 | 2015 | 29 | 0.140 |
Why?
|
Midazolam | 1 | 2016 | 10 | 0.140 |
Why?
|
Anesthetics, Intravenous | 1 | 2016 | 17 | 0.140 |
Why?
|
Housing | 2 | 2014 | 65 | 0.140 |
Why?
|
Sleep Apnea Syndromes | 1 | 2016 | 27 | 0.140 |
Why?
|
Fentanyl | 1 | 2016 | 32 | 0.140 |
Why?
|
Respiratory Distress Syndrome, Adult | 1 | 2016 | 52 | 0.130 |
Why?
|
Physical Therapy Modalities | 1 | 2016 | 64 | 0.130 |
Why?
|
Prospective Studies | 4 | 2019 | 2278 | 0.130 |
Why?
|
Treatment Outcome | 3 | 2013 | 3302 | 0.130 |
Why?
|
Respiration, Artificial | 1 | 2016 | 98 | 0.130 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 474 | 0.130 |
Why?
|
Poultry | 1 | 2015 | 27 | 0.120 |
Why?
|
Length of Stay | 1 | 2016 | 314 | 0.120 |
Why?
|
Infant | 2 | 2015 | 1059 | 0.120 |
Why?
|
Food-Processing Industry | 1 | 2015 | 40 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2015 | 58 | 0.120 |
Why?
|
Risk Factors | 5 | 2014 | 3867 | 0.120 |
Why?
|
Child, Preschool | 2 | 2015 | 1268 | 0.120 |
Why?
|
Oximetry | 2 | 2016 | 31 | 0.120 |
Why?
|
Air Pollution, Indoor | 1 | 2014 | 9 | 0.120 |
Why?
|
Immunocompromised Host | 1 | 2014 | 51 | 0.110 |
Why?
|
Health Status | 2 | 2016 | 399 | 0.110 |
Why?
|
Patient Education as Topic | 1 | 2015 | 271 | 0.110 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2014 | 94 | 0.110 |
Why?
|
Adenoma, Pleomorphic | 1 | 2013 | 2 | 0.110 |
Why?
|
Granular Cell Tumor | 1 | 2013 | 2 | 0.110 |
Why?
|
Bronchial Diseases | 1 | 2013 | 4 | 0.110 |
Why?
|
Infant, Newborn | 1 | 2015 | 668 | 0.110 |
Why?
|
Papilloma | 1 | 2013 | 9 | 0.110 |
Why?
|
Hamartoma | 1 | 2013 | 10 | 0.110 |
Why?
|
Mediastinal Diseases | 1 | 2012 | 4 | 0.110 |
Why?
|
Leiomyoma | 1 | 2013 | 16 | 0.110 |
Why?
|
Biopsy, Needle | 1 | 2012 | 93 | 0.100 |
Why?
|
Respiratory Aspiration | 2 | 2009 | 21 | 0.100 |
Why?
|
Case-Control Studies | 3 | 2017 | 893 | 0.100 |
Why?
|
Sex Factors | 1 | 2014 | 661 | 0.100 |
Why?
|
Poultry Products | 1 | 2012 | 14 | 0.100 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2012 | 7 | 0.100 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 183 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2012 | 107 | 0.100 |
Why?
|
Bronchi | 2 | 2009 | 33 | 0.100 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 240 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2014 | 766 | 0.100 |
Why?
|
Sensitivity and Specificity | 2 | 2010 | 582 | 0.100 |
Why?
|
Obesity | 2 | 2016 | 1175 | 0.100 |
Why?
|
Drug Combinations | 1 | 2012 | 98 | 0.100 |
Why?
|
Smoking Cessation | 1 | 2014 | 198 | 0.100 |
Why?
|
Child | 2 | 2015 | 2436 | 0.100 |
Why?
|
Homeless Persons | 1 | 2011 | 4 | 0.100 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 288 | 0.090 |
Why?
|
Blood Pressure Monitors | 1 | 2010 | 2 | 0.090 |
Why?
|
Risk | 1 | 2012 | 320 | 0.090 |
Why?
|
Family Characteristics | 1 | 2011 | 36 | 0.090 |
Why?
|
Incidence | 1 | 2014 | 1196 | 0.090 |
Why?
|
Electronic Mail | 1 | 2010 | 18 | 0.090 |
Why?
|
Physician's Role | 1 | 2010 | 40 | 0.090 |
Why?
|
Focus Groups | 1 | 2010 | 113 | 0.090 |
Why?
|
Data Collection | 1 | 2010 | 180 | 0.090 |
Why?
|
Critical Illness | 1 | 2010 | 87 | 0.090 |
Why?
|
Critical Care | 1 | 2010 | 107 | 0.090 |
Why?
|
European Continental Ancestry Group | 1 | 2014 | 1166 | 0.090 |
Why?
|
Disease Progression | 1 | 2012 | 593 | 0.090 |
Why?
|
Prescriptions | 1 | 2009 | 12 | 0.080 |
Why?
|
Blood Gas Analysis | 1 | 2009 | 17 | 0.080 |
Why?
|
Pleural Effusion | 1 | 2009 | 13 | 0.080 |
Why?
|
Trachea | 1 | 2009 | 52 | 0.080 |
Why?
|
African Americans | 1 | 2014 | 1425 | 0.070 |
Why?
|
Cohort Studies | 3 | 2017 | 1813 | 0.070 |
Why?
|
Respiratory Function Tests | 2 | 2015 | 100 | 0.060 |
Why?
|
Health Surveys | 2 | 2013 | 196 | 0.050 |
Why?
|
Lung | 2 | 2014 | 249 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2019 | 293 | 0.040 |
Why?
|
Cholinergic Antagonists | 1 | 2017 | 10 | 0.040 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2017 | 9 | 0.040 |
Why?
|
Vital Capacity | 1 | 2017 | 40 | 0.040 |
Why?
|
Administration, Inhalation | 1 | 2017 | 54 | 0.040 |
Why?
|
Forced Expiratory Volume | 1 | 2017 | 87 | 0.040 |
Why?
|
Demography | 1 | 2016 | 109 | 0.030 |
Why?
|
Outpatients | 1 | 2016 | 57 | 0.030 |
Why?
|
Neck | 1 | 2016 | 27 | 0.030 |
Why?
|
Office Visits | 1 | 2016 | 73 | 0.030 |
Why?
|
Hand Strength | 1 | 2016 | 101 | 0.030 |
Why?
|
Biopsy | 1 | 2017 | 259 | 0.030 |
Why?
|
Insurance, Health | 1 | 2016 | 95 | 0.030 |
Why?
|
Resistance Training | 1 | 2016 | 82 | 0.030 |
Why?
|
Mental Health | 1 | 2016 | 117 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 351 | 0.030 |
Why?
|
Patient Discharge | 1 | 2016 | 188 | 0.030 |
Why?
|
Lymphatic Diseases | 1 | 2014 | 10 | 0.030 |
Why?
|
Mediastinal Neoplasms | 1 | 2014 | 13 | 0.030 |
Why?
|
Infectious Disease Medicine | 1 | 2014 | 4 | 0.030 |
Why?
|
Cockroaches | 1 | 2014 | 2 | 0.030 |
Why?
|
Rodentia | 1 | 2014 | 9 | 0.030 |
Why?
|
Spirometry | 1 | 2014 | 27 | 0.030 |
Why?
|
Puerto Rico | 1 | 2013 | 11 | 0.030 |
Why?
|
Health Status Indicators | 1 | 2014 | 73 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2017 | 881 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 128 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2014 | 158 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2014 | 263 | 0.030 |
Why?
|
Body Mass Index | 1 | 2016 | 922 | 0.030 |
Why?
|
Medical Oncology | 1 | 2014 | 86 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 130 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 166 | 0.030 |
Why?
|
Animals | 2 | 2015 | 7541 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 297 | 0.030 |
Why?
|
Accidents, Occupational | 1 | 2011 | 16 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2012 | 462 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2012 | 447 | 0.020 |
Why?
|
Respiratory Sounds | 1 | 2011 | 9 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 149 | 0.020 |
Why?
|
Community-Based Participatory Research | 1 | 2011 | 114 | 0.020 |
Why?
|
Models, Statistical | 1 | 2011 | 173 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 367 | 0.020 |
Why?
|
Odds Ratio | 1 | 2011 | 472 | 0.020 |
Why?
|
Prognosis | 1 | 2013 | 1495 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2011 | 683 | 0.020 |
Why?
|
Laboratories, Hospital | 1 | 2009 | 3 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2009 | 66 | 0.020 |
Why?
|
Logistic Models | 1 | 2011 | 778 | 0.020 |
Why?
|
Transducers | 1 | 2008 | 11 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2008 | 53 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2008 | 99 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2008 | 185 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2008 | 190 | 0.020 |
Why?
|